Polarean Imaging Share Discussion Threads

[loglorry1] 24/1/2020 09:16

While I'm very bullish here we need to not get too carried away. I'm not sure the 250K was a buy could have just been someone moving some stock around I don't know. The shares are still very cheap but I'd rather see a nice steady climb as we approach very exciting news flow.

[diversification] 24/1/2020 08:42

We could again see an RNS for a director dealing today following yesterday’s £250k purchase.

Would not surprise me if Allis continues to add to his position given his relatively low exposure.

[dafad] 24/1/2020 08:09

40p today i reckon.gla

[adorling] 23/1/2020 20:13

One helluva breakout and momentum building so just imagine where we will be when positive trial results are revealed (un-blinded)? - Remember all we need to prove is non-inferiority for Licence submission. Got to be one of the best risk-reward investment on AIM IMHO.

[dafad] 23/1/2020 17:50

£250k buy gone through at 35.5p

[dafad] 23/1/2020 13:44

More directors buying today i wonder??

[kop202] 23/1/2020 13:38

Non- exec buys ~100k's worth...hence the share price jump

[moneymachine2] 23/1/2020 13:35

Adding more when I can, looks very good.

[kop202] 23/1/2020 13:26

Fair enoughI'm a QFI survivor ....still hanging on... so are underwater I'll need to go into a decompression chamber if I ever get into profit..... what a bunch of rogues in suites they turned out to be.

[loglorry1] 23/1/2020 13:13

KoP funds will get involved when market cap is much higher probably £50m. I think the shares are tightly held so any buying here now will have a dramatic upward relate.

Worrying about a few p here will look silly when it's over £1.

[kop202] 23/1/2020 12:56

Good post LogSounds like you have done your homeworkBut like everything else on AIM...Trading through an intermediary..skulduggery by the City traders causing share price overhangs at willAnd then there are the Funds who instruct brokers to get them shares....which won't be at current market prices...more potential misery for pi's

[loglorry1] 23/1/2020 11:15

BlueEarth had approval and sales when it was sold so it was de-risked compared to Polarean and it was a different clinical area. It's hard to say if that clinical area is more or less important/lucrative.

There are a lot of lung diseases and use cases for POLX's product which basically makes lung function visible in 3D where it was pretty opaque before. To me that sounds like a pretty incredible medical step.

So what risk should we apply for Polarean at it's earlier stage? Phase III would normally be quite high risk but as discussed its lower due to the type of trial and clear evidence that 129XE is non-inferior already. So I'd say chance of approval at least 75%. Then we have risk of them hitting the sales projections. That to me sounds low too as they have already sold 25 units for research so let's say 75% chance they hit targets but there's probably a good chance they go over and even if they don't sales will cover a much higher market cap.

So very conservatively speaking I'd say there was a 70% chance they'll grow to a market cap as big as Blue Earth within a year or two. I'm not sure you'll get better odds on a ten bagger anywhere else!

[diversification] 22/1/2020 21:30

This is why it's not inconceivable to see a market value of £200m + after or possibly even before FDA approval in approx 1/2Q 2021. Current market cap is ridiculously cheap, especially upon Phase 3 results.

[rhatton] 22/1/2020 20:51

So we’re a few years away from generating that kind of revenue but definitely achievable if everything goes to plan. Within the first 48 months post approval they’re looking at 1000 hospitals which will be approx $500million without recurring revenue i guess

[diversification] 22/1/2020 20:29

Blue Earth Diagnostics employs approximately 100 people and is expected to generate revenues of $ 140M in the year to September 2019, primarily in the US.Polx has a £36m market cap. By compassion Blue earth was sold for £342m. You can see the discrepancy that will narrow over time for a company with exposure to a larger market. I don't mean to sound ramptastic but the numbers speak volumes.

[rhatton] 22/1/2020 20:20

At what stage we’re Blue Earth sold? We’re they revenuegenerating?

[diversification] 22/1/2020 19:59

When considering the size of the market for Blue Earth for prostrate cancer it is expected to reach a global annual value of $12billion a year by 2025. Obviously as per POLX, Blue earth will absorb a proportion of the revenue from this market. By comparison the target for POLX is $150billion with other target markets possible with their IP. This puts into consideration the prospective valuation of POLX when Blue earth was sold for $450m.Mind blowing potential.

[loglorry1] 22/1/2020 18:10

AIUI Blue Earth has a product where you inject some sort of agent in or around prostate cancer cells and under a PET scan (I think) it allows a physician to visualise the extent, shape etc of the tumour.

I suspect each treatment demands a fee. So yes similar to POLX in many ways.

[diversification] 22/1/2020 18:00

I am struggling to identify if Blue earth Diagnostics had a similar business model to POLX in that it could sell the machine and also have ongoing revenue from each scan and maintenance? It's this reoccurring revenue with POLX that has me most interested in the company. Correct, Justin not Justine, my bad.

[loglorry1] 22/1/2020 17:17

Italian company Bracco Imaging has signed a definitive agreement to acquire all outstanding shares of UK molecular imaging company Blue Earth Diagnostics in a deal valued at $450m.

Blue Earth Diagnostics CEO Dr Jonathan Allis said: “The acquisition of Blue Earth Diagnostics by Bracco Imaging is a validation of the proven success of Axumin in prostate cancer, its potential uses beyond prostate cancer, and the PSMA pipeline under development.

[loglorry1] 22/1/2020 17:13

I'm not a huge fan of Justin's (not Justine by the way) but I think in this case he has got it right. There is a lot of overvalued over promoted rubbish on AIM but POLX is not in that category. If anything management of POLX are vastly understating its potential. In any case you just need to follow the money and the buy today is a significant vote of confidence from someone with an amazing track record in this field.

He's done it before with Blue Earth and existed at a valuation of $450m.

[diversification] 22/1/2020 17:04

You lucky individual! I wish I knew about this company at the time. It was a Justine W podcast over Christmas that drew my attention to this, usually an unlikely source but I think his on the number with this one.

[loglorry1] 22/1/2020 16:59

I took part in the Amphion clean up and I've not sold a single share. I will be holding onto them very tightly. The market cap has a long way to go yet.

[diversification] 22/1/2020 16:54

At 44p this is only a 50m market cap. It's far to cheap given what we know about forward projected P.E. following FDA approval. This has a very low float and it's shrinking by the day.